Krystal Biotech (NASDAQ:KRYS) Sets New 52-Week High – Should You Buy?

Posted by Brenda Bartman on Jun 25th, 2026

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) reached a new 52-week high on Thursday . The stock traded as high as $358.45 and last traded at $360.93, with a volume of 67579 shares trading hands. The stock had previously closed at $347.63.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. HC Wainwright lifted their target price on shares of Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a research note on Tuesday, June 16th. Citigroup lifted their target price on shares of Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Wall Street Zen cut Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. TD Cowen increased their target price on Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. Finally, Evercore restated an “outperform” rating and issued a $300.00 price target on shares of Krystal Biotech in a research note on Tuesday, May 5th. Ten investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $340.56.

Read Our Latest Analysis on KRYS

Krystal Biotech Trading Up 2.4%

The company’s 50-day moving average is $300.85 and its 200-day moving average is $275.14. The firm has a market cap of $10.50 billion, a price-to-earnings ratio of 47.37 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last released its earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The firm had revenue of $116.36 million during the quarter, compared to analysts’ expectations of $112.11 million. Equities research analysts forecast that Krystal Biotech, Inc. will post 7.66 EPS for the current year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the sale, the insider owned 1,378,155 shares in the company, valued at $424,623,337.05. This trade represents a 1.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 642 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $302.03, for a total transaction of $193,903.26. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 13.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

Several hedge funds have recently modified their holdings of the company. Sound Income Strategies LLC increased its holdings in Krystal Biotech by 1,270.0% in the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after purchasing an additional 127 shares in the last quarter. Western Wealth Management LLC bought a new position in shares of Krystal Biotech during the first quarter valued at $34,000. Greenline Wealth Management LLC acquired a new position in shares of Krystal Biotech during the fourth quarter worth $34,000. Danske Bank A S acquired a new stake in Krystal Biotech in the third quarter valued at $35,000. Finally, UMB Bank n.a. boosted its position in Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after acquiring an additional 37 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Company Profile

(Get Free Report)

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.